Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q3 2021 · 10-Q
Revenue$6.20M$6.20M−90.1% vs Q3 2020 Net Income-$39.08M-$39.08MN/M vs Q3 2020 EPS Diluted-$0.57-$0.57N/M vs Q3 2020 Operating Income-$39,253,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$43,129,000N/M Margins · derivedOperating margin-633.4%−647.7 pt vs Q3 2020
Net margin-630.7%−643.1 pt vs Q3 2020
ended Sep 30, 2021 · filed Nov 9, 2021 · 40 d after period end